PLX-PAD细胞治疗严重下肢缺血:PACE试验的设计与依据
PACE是一项III期随机双盲多中心安慰剂对照试验,评估肌内注射PLX-PAD细胞治疗不适合血运重建的Rutherford 5级严重下肢缺血患者的疗效与安全性。计划入组246例,按2:1随机接受PLX-PAD 300×10^6细胞或安慰剂两次注射,间隔8周,主要终点为免截肢生存时间。
要点
- PLX-PAD为现货型异体胎盘来源间充质样细胞,临床前显示促血管生成、抗炎和再生特性。
- PACE试验针对不适合血运重建或风险获益不利的Rutherford 5级严重下肢缺血患者。
- 主要疗效终点为免截肢生存时间,随访至少12个月、最长36个月。
核心结论
- 基于有利的临床前和早期临床结果,PACE III期随机对照试验将评估胎盘来源PLX-PAD细胞治疗对血运重建风险获益不利的严重下肢缺血患者的疗效。
研究设计与样本
- PACE为III期随机、双盲、多中心、多国、安慰剂对照、平行组研究。
- 计划入组246例动脉粥样硬化性严重下肢缺血伴轻微组织缺损(Rutherford 5级)至踝水平的患者。
- 患者按2:1随机接受肌内注射PLX-PAD 300×10^6细胞或安慰剂,共两次,间隔8周。
主要发现
- 两项小型开放标签I期试验显示有利的1年免截肢生存,并有疼痛评分降低和组织灌注增加的趋势。
- 临床前研究显示PLX-PAD具有促血管生成、抗炎和再生特性。
关键数值与推荐
- 主要疗效终点为至重大截肢或死亡的时间(免截肢生存),随访至少12个月、最长36个月。
- 入组患者为不适合血运重建或血运重建风险获益不利者。
- PLX-PAD剂量为300×10^6细胞,肌内注射两次,间隔8周。
临床怎么用
- 该试验针对无血运重建选择的严重下肢缺血患者,探索异体细胞治疗的获益与安全性。
- 研究结果可能为严重下肢缺血提供一种现货型细胞治疗选择。
局限性
- 原文为试验设计文章,尚未报告PACE试验的疗效和安全性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Critical limb ischaemia (CLI) is a life threatening condition with a considerable risk of major amputation and death. Besides revascularisation, no treatment has been proven to reduce the risks. Therapeutic angiogenesis by gene or cell therapy has not demonstrated definitive evidence in randomised controlled trials. PLX-PAD is an "off the shelf" allogeneic placental derived, mesenchymal like cell therapy, which, in preclinical studies, has shown pro-angiogenic, anti-inflammatory, and regenerative properties. Favourable one year amputation free survival (AFS), and trends in reduction of pain scores and increase of tissue perfusion have been shown in two small, open label, phase I trials. METHODS: The PACE study is a phase III randomised, double blind, multicentre, multinational placebo controlled, parallel group study to evaluate the efficacy, tolerability, and safety of intramuscular injections of PLX-PAD cells to treat patients with atherosclerotic CLI with minor tissue loss (Rutherford Category 5) up to the ankle level, who are unsuitable for revascularisation or carry an unfavourable risk benefit for that treatment. The study will enroll 246 patients, who after screening are randomised in a ratio of 2:1 to treatment with intramuscular injections of PLX-PAD 300 × 106 cells or placebo on two occasions, eight weeks apart. The primary efficacy endpoint is time to major amputation or death (amputation free survival), which will be assessed in follow up of at least 12 months and up to 36 months. CONCLUSIONS: Based on favourable pre-clinical and initial clinical study results, the PACE phase III randomised controlled trial will evaluate placenta derived PLX-PAD cell treatment in patients with critical limb ischaemia, with an unfavourable risk benefit for revascularisation. Clinicaltrials.gov: NCT03006770.
引用
- Norgren L, Weiss N, Nikol S, et al. PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial. Eur J Vasc Endovasc Surg. 2019. PMID: 30686676. doi:10.1016/j.ejvs.2018.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。